other dosage forms:
cushing
syndrome
long duration of therapy
high doses of medroxyprogesterone
doses
hormonal replacement therapy
long-term contraception
cushing
syndrome
medroxyprogesterone
mild glucocorticoid activity
cases of medroxyprogesterone-induced cushing
syndrome
low cortisol
adrenocorticotrophic hormone
acth
levels with a
reduced pituitary-adrenal reserve
acute adrenal insufficiency
following withdrawal of medroxyprogesterone
endocrine side effects
breast tenderness
galactorrhea
hyperprolactinemia
prevention of lactation
hirsutism
cushing
syndrome
weight gain
weight loss during medroxyprogesterone therapy
women
using intramuscular medroxyprogesterone for contraception
mean weight gain
year of therapy
kg
years
patients
mean
kg
data
effect of medroxyprogesterone on lipid profiles
been conflicting
studies
possible negative effects on lipid profiles while others
reduction in total
low-density lipoprotein cholesterol
increase in high-density lipoprotein cholesterol levels
metabolic side effects
weight changes
increases
decreases
glucose intolerance
changes in serum cholesterol concentrations
genitourinary side effects
menstrual changes
amenorrhea
irregular bleeding
spotting
heavy bleeding
vaginal cysts
dyspareunia
changes in cervical erosion
secretions
endometrial hyperplasia
medroxyprogesterone
favorable effect on the endometrium
changes in libido
anorgasmia
withdrawal bleeding
common complaint among postmenopausal women
days per cycle
medroxyprogesterone therapy
postmenopausal women
receiving continuous medroxyprogesterone
estrogen therapy
year of therapy
women
receiving medroxyprogesterone for contraception
year of therapy
women on estrogen replacement therapy
addition of medroxyprogesterone
other progestin
days of each cycle
risk of endometrial hyperplasia
risk of endometrial carcinoma
low-dose continuous medroxyprogesterone therapy
risk of endometrial hyperplasia
use of unopposed estrogen
patients
abnormal bleeding
possibility of an organic pathology
significant increase in the incidence of breast cancer in beagle dogs in addition
apparent increase in the incidence of endometrial cancer in rhesus monkeys
early animal carcinogenicity studies
international
long-term studies
risk of medroxyprogesterone in humans
world health organization
increased risk of cancer in users of medroxyprogesterone
significant increase in the risk of breast cancer
cervical cancer
epithelial ovarian cancer
data from these studies
fold
reduction in the incidence of endometrial cancer among medroxyprogesterone users
study from new zealand
women
taking depot medroxyprogesterone acetate
higher risk for breast cancer during the first years
therapy for more than years
increased risk of breast cancer
oncologic side effects
medroxyprogesterone
topic of considerable debate
data from some animal studies
increased risk of breast
endometrial cancer
current consensus
carcinogenic potential of medroxyprogesterone
other hormonal contraceptives
majority of cases of thromboembolic disease during hormonal therapy
estrogens
progestins
medroxyprogesterone
high doses
hypercoagulable state
development of thrombotic events
medroxyprogesterone
edema
patients
underlying disease
migraine headaches
asthma
heart disease
renal dysfunction
seizure disorders
edema
fluid retention
cardiovascular
side effects
thromboembolic disorders
thrombophlebitis
deep vein thrombosis
pulmonary embolism
cerebrovascular accidents
retinal thrombosis
addition
edema
hypertension
tachycardia
syncope
musculoskeletal side effects
changes in bone mineral density
leg cramps
reductions in bone mineral density
osteoporosis
medroxyprogesterone
such effects
medroxyprogesterone-induced estrogen deficiency
conflicting data
effects of medroxyprogesterone on bone mineral density
study
women
years of age
receiving medroxyprogesterone mg
months
more years for long-term contraception
reduction in bone mineral density
premenopausal controls
bone mineral density in the treatment group
postmenopausal controls
study of women
medroxyprogesterone mg
months for a median duration of years
range
years
bone density
medroxyprogesterone users
bone mineral density in women
starting depot medroxyprogesterone after the age of years
using
fewer years
remainder of the cohort
study
potential for postmenopausal fracture
residual effects of depot medroxyprogesterone in former users
risk
substantial impact in postmenopausal women
significant differences in bone density
women
used depot medroxyprogesterone for > yeas
trend toward lower bone densities
bone density in women
receiving long-term depot medroxyprogesterone for a mean of years
range
years
normal population
decreased estrogen levels
dermatologic side effects
acne
hair growth
alopecia
melasma
chloasma
rash
excessive sweating
dry skin
scleroderma
erythema multiforme
erythema nodosum
nervous system
side effects
headache
asthenia
dizziness
depression
somnolence
insomnia
paresthesias
convulsions
facial palsy
causality
gastrointestinal side effects
patients
nausea
abdominal pain
bloating
anorexia
hepatic side effects
elevations in liver function tests
jaundice
cholestatic jaundice
cholelithiasis
hematologic side effects
rare reports of hypercoagulability
thromboembolic activity
hypersensitivity side effects
urticaria
angioneurotic edema
anaphylaxis
anaphylactoid reactions
local side effects
intramuscular administration of medroxyprogesterone
pain
change in skin color
residual lumps
sterile abscesses at the injection site
ocular side effects
visual disturbances
sudden loss of vision
sudden onset of proptosis
diplopia
migraine
therapy
presence of papilledema
retinal vascular lesions
psychiatric side effects
dysphoric symptoms
premenstrual syndrome
pms
intramuscular suspension
stomach pain
irregular menstrual periods
anxiety
blurred vision
breast pain
tenderness
changes in skin color
chills
clay-colored stools
cough
dark urine
decrease in amount of urine
diarrhea
difficulty swallowing
dizziness or lightheadedness
eye pain
fainting
fast heartbeat
fever
headache
hives
welts
itching
redness
swelling
skin rash
hive-like swelling on the face
eyelids
lips
tongue
throat
hands
legs
feet
sex organs
loss of appetite
menstrual changes
nausea
noisy, rattling breathing
pain in the chest
groin
legs
calves
pain
tenderness
swelling of the foot
leg
puffiness
swelling of the eyelids
eyes
face
lips
tongue
severe, sudden headache
shortness of breath
slurred speech
stopping of menstrual bleeding
sudden loss of coordination
severe weakness
numbness in the arm
leg
unexplained shortness of breath
swelling of the fingers
hands
feet
lower legs
troubled breathing at rest
excess milk flow from the breasts
unpleasant breath odor
unusual tiredness
weakness
vaginal bleeding
spotting
vision changes
vomiting of blood
weight gain
yellow eyes
skin
blemishes on the skin
discouragement
feeling
hair loss
thinning of hair
increased hair growth
face
irritability
lack of appetite
loss of interest
pleasure
nervousness
pimples
sleepiness
unusual drowsiness
tiredness
trouble concentrating
trouble sleeping
weight changes